Actualités

GILD wins FDA approval to expand Trodelvy into first-line metastatic triple-negative breast cancer, opening a broader treatment opportunity.

Merck wins EU approval for Keytruda plus Padcev in patients with resectable muscle-invasive bladder cancer who are ineligible for cisplatin-based chemotherapy.

Bio-Techne (TECH) said Thursday it has agreed to be acquired by Merck KGaA in an all-cash deal with

Watch Fireside Chat Below, or Click HERE: Exec Edge hosted a fireside chat with NanoViricides, Inc. (NYSE: NNVC) President and Executive Chairman Anil R. Diwan, PhD, moderated by IPO Edge […]

Shares of Bio-Techne surged before the opening bell on Thursday after Germany’s Merck KGaA announced it has agreed to purchase the company for $11.3 billion. Bio-Techne stock jumped 21% to $70.95 in premarket trading on Thursday. Merck KGaA plans to acquire Bio-Techne for $73 a share, according to the media release, representing a 24% premium based on the stock’s closing price from Wednesday.

Germany’s Merck KGaA has announced a major acquisition agreement to buy U. S.

June 25 () - Merck KGaA has agreed to ‌acquire biotech firm Bio-Techne ‌Corp for $11.3 billion, the German science ​and healthcare firm said in a statement on Thursday.

Merck KGaA offered $73 a share in cash for Bio-Techne, representing a 24% premium to the U.S. lab-tools supplier’s closing price Wednesday.

7.50am: 3i reveals slower growth for Action 3i Group said its largest portfolio company, Action, remains on track for a good second quarter despite like-for-like sales growth slowing. Ahead of its annual general meeting on Thursday, the FTSE 100-listed private equity investor said European...

Merck & Co., Inc. (NYSE:MRK) is included among the 10 Reliable Dividend Stocks to Buy for Long-Term Investors. On June 24, CICC initiated coverage of Merck & Co., Inc. (NYSE:MRK) with an Outperform rating. It also set a $138 price target on the stock. Merck also provided an updated outlook during its first-quarter 2026 earnings call. […]

AbbVie's post-Humira growth story has been a triumph, but the single drug driving that narrative is showing the first hint of a slowdown.

Gilead secures EC approval to expand Trodelvy into first-line metastatic TNBC, marking a new treatment option and broadening its oncology reach.

We recently compiled a list of the 10 Best Weight Loss Drug Stocks to Buy in 2026. Merck & Co., Inc. (NYSE:MRK) is one of the best weight loss drugs on this list. TheFly reported on June 18 that MRK announced that the U.S. Food and Drug Administration (FDA) granted an expanded approval for Capvaxive, extending its […]

Pre-Market Stock Futures: Futures are trading higher this morning, but if you’ve ever heard the old saying, “when the chips are down”, that was the poster child phrase for Tuesday’s session, as technology stocks, and specifically the semiconductor stocks, followed a worldwide sell-off that initially began in Korea and carried around the globe. When ... Here Are Wednesday’s Best Wall Street Analyst Research Calls: Devon Energy, Flowserve, Klaviyo, Macerich, Merck, Nucor, Take-Two Interactive Soft

In June 2026, Merck reported positive Phase 3 results for its anti-TL1A antibody tulisokibart in moderately to severely active ulcerative colitis, alongside recent US FDA approvals expanding KEYTRUDA–WELIREG use in kidney cancer and CAPVAXIVE’s indication to higher-risk children and adolescents. Together, these updates highlight Merck’s push to broaden its portfolio beyond oncology by advancing late-stage immunology assets and deepening its vaccines and cancer franchises. We’ll now examine...

Before its fifty percent surge, the drug giant was repeatedly telling a story about its future that the market seemed to be ignoring.

Healthcare stocks rose late Tuesday afternoon, with the NYSE Healthcare Index adding 1.5% and the St

We just covered the 10 Stocks That Will 10X According to Social Media. Tempus AI (NASDAQ:TEM) ranks #7 (see 5 Stocks That Will 10X According to Social Media). Number of Hedge Fund Investors: 33 Tempus AI (NASDAQ:TEM) runs cancer diagnostic tests and sells the resulting data and AI tools to pharmaceutical companies and research institutions. […]

Exelixis falls after STELLAR-303 misses statistical significance in overall survival for a key colorectal cancer subgroup, raising approval uncertainty.

MRK's tulisokibart meets goals in a late-stage ulcerative colitis study, strengthening a key pipeline asset as the company looks beyond Keytruda.

PFE's phase III NSCLC study misses a key survival goal overall, but a large subgroup shows favorable survival trends vs docetaxel.

Bank of America has predicted that the Federal Reserve will be forced to raise interest rates by 75 basis points this year, with the first 25-basis-point hike in September. They also see additional 25-basis-point hikes in October and December. The energy shock from the war with Iran drove inflation higher, with the CPI rising in ... Bank of America Sees Interest Rates Exploding Higher Soon: Play It Safe With 4 Dividend Giants

The drugmaker has successfully replaced its former blockbuster, but buying into that victory today means paying a steep premium for its next act.

A short straddle is an advanced options strategy used when a trader is seeking to profit from an underlying stock trading in a narrow range.

While Wall Street fretted over the future of its biggest blockbuster, a pair of new drugs were already showing the company's next act was well underway.

ABBV's successful transition beyond Humira and growth from newer medicines give it an edge over MRK in this oncology-immunology showdown.

Houman Ashrafian is leaving Sanofi to pursue a new opportunity. Elsewhere, one of Merck’s prized immune drugs succeeded in a pivotal study and a psychedelics biotech’s shares surged.

Merck (NYSE:MRK) received FDA approval for expanded use of KEYTRUDA and KEYTRUDA QLEX with WELIREG as adjuvant treatment in certain renal cell carcinoma patients. The FDA also granted expanded approval for CAPVAXIVE in children and adolescents at higher risk for pneumococcal disease, making it the only PCV indicated for this US group. Merck and Gilead reported positive Phase 3 data for a once weekly oral HIV treatment regimen. Separately, Merck discontinued a Phase 3 lung cancer trial...

Merck & Co., Inc. (NYSE:MRK) is one of Kevin O’Leary’s top stock picks for 2026 through the O’Shares U.S. Quality Dividend ETF. The stock made up 2.91% of the ETF as of June 17, 2026. On June 12, 2026, Merck said the US FDA approved KEYTRUDA and the easier-to-administer KEYTRUDA QLEX, each with WELIREG, for […]

The Health Care Select Sector SPDR ETF (NYSEARCA:XLV) is having a frustrating year. The fund sits at $149, down about 3% year-to-date while the broader market grinds higher. The good news for XLV holders: the fund has clawed back roughly 14% over the past year, and the 2026 setup looks meaningfully different from the policy ... The 2 Factors That Will Decide Whether XLV Finally Catches the S&P 500 in 2026